Nektar Therapeutics ( NASDAQ:NKTR ) investors will be delighted, with the company turning in some strong numbers ...

DelveInsight's 'NK Cell Therapy Pipeline Insight 2024' report provides comprehensive global coverage of pipeline NK cell ...

Nektar Therapeutics ( (NKTR) ) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...

Nektar Therapeutics (NASDAQ:NKTR) is scheduled to announce Q3 earnings results on Thursday, November 7th, after market close.

SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Thursday reported a loss of $37.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it ...

The presentations will be accessible via the webcast links above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and ...

Nektar Therapeutics today reported financial results for the third quarter ended September 30, 2024. Cash and investments ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

For Ampersand, the Avid deal closely follows the acquisition of Nektar Therapeutics’ commercial-scale manufacturing facility ...